A Phase 2, Randomized, Double-blind Trial To Evaluate The Safety And Immunogenicity Of A Multivalent Pneumococcal Conjugate Vaccine In Adults 60 Through 64 Years Of Age
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 16 Feb 2018
At a glance
- Drugs Pneumococcal vaccine conjugate (Primary)
- Indications Pneumococcal infections
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Pfizer
- 14 Dec 2017 Planned End Date changed from 21 Dec 2018 to 10 Dec 2018.
- 14 Dec 2017 Planned primary completion date changed from 21 Dec 2018 to 10 Dec 2018.
- 14 Dec 2017 Status changed from recruiting to active, no longer recruiting.